In the 308-person REMAIN-1 study, Revita patients held onto about 80% of their lost weight versus 67% with sham. Fractyl plans an FDA filing in late 2026.
Recap by typeshit. Full story at Quiver Quantitative.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Moneycontrol says the Indian drugmaker is focusing on specialised production of peptides and antibody-drug conjugates rather than crowded weight loss drugs.
Foundayo prescriptions rose from 57,920 the week before in its 27th week on sale. Oral Wegovy still leads on volume but fell from about 180K.
Loading…